| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥8823.3B | ¥8750.3B | +0.8% |
| Operating Income | ¥700.6B | ¥664.5B | +5.4% |
| Ordinary Income | ¥724.0B | ¥650.4B | +11.3% |
| Net Income | ¥426.5B | ¥465.3B | -8.3% |
| ROE | 5.3% | 5.9% | - |
FY2025 Q3 cumulative results show Revenue of 882.3B yen (YoY +0.8%), Operating Income of 70.1B yen (YoY +5.4%), Ordinary Income of 72.4B yen (YoY +11.3%), and Net Income of 42.7B yen (YoY -8.3%). While top-line growth was modest at 0.8%, operating income improved by 5.4% through margin expansion, with operating margin reaching 7.9% (up from 7.6% in prior year). However, net income declined 8.3% due to special losses of 4.6B yen (impairment charges) and higher tax burden with an effective tax rate of approximately 35.0%. The company reported operating cash flow of only 4.3B yen, representing just 0.11x of net income, indicating significant earnings quality concerns. Free cash flow was negative 71.5B yen driven by substantial capital expenditures of 67.3B yen, reflecting aggressive growth investments at 1.65x depreciation. Total assets increased to 1,305.8B yen with equity ratio maintained at 62.0%, while long-term borrowings surged 355.3% to 56.6B yen, signaling a shift in capital structure to fund investments.
Revenue increased 0.8% YoY to 882.3B yen, comprised of Food segment sales of 711.1B yen (up 1.3% from 700.9B yen prior year) and Pharmaceutical segment sales of 172.2B yen (down 1.1% from 174.1B yen). The Food segment contributed 80.6% of total revenue and demonstrated resilience with positive growth despite challenging market conditions. Pharmaceutical segment experienced slight contraction, though remained stable overall. Operating income improved 5.4% to 70.1B yen, with Food segment operating income rising 8.4% to 5.4B yen and Pharmaceutical segment operating income increasing 1.1% to 2.1B yen. The improvement in operating profit was driven by margin expansion through cost management, as SG&A expenses as percentage of sales declined to 22.6% from prior levels. Gross profit margin held steady at 30.5%, indicating stable pricing power and procurement efficiency. Corporate expenses increased to 4.2B yen from 3.4B yen, reflecting higher holding company operational costs. Ordinary income of 72.4B yen exceeded operating income by 2.3B yen, indicating positive contribution from non-operating items including equity method gains and financial income. However, net income declined 8.3% to 42.7B yen due to non-recurring factors including special losses of 4.6B yen related to impairment charges and higher income tax expenses of 23.0B yen. The gap between ordinary income of 72.4B yen and net income of 42.7B yen represents 41.1%, explained by tax burden of 23.0B yen (31.8% of the gap) and extraordinary losses. This represents a revenue up/profit down pattern at the net income level, though operating profit improved.
Food segment generated revenue of 711.1B yen with operating income of 5.4B yen, representing an operating margin of 0.8%. This segment is the core business accounting for 80.6% of consolidated revenue and 72.3% of segment operating income. Pharmaceutical segment recorded revenue of 172.2B yen with operating income of 2.1B yen, yielding a significantly higher operating margin of 1.2%. Despite being smaller in scale at 19.5% of revenue, Pharmaceutical contributes 27.7% of segment operating income, demonstrating superior profitability characteristics. The margin differential of 0.4 percentage points between segments reflects the higher value-added nature of pharmaceutical operations. Both segments showed operating income growth, with Food up 8.4% YoY and Pharmaceutical up 1.1% YoY, contributing to overall consolidated operating profit expansion. Corporate adjustments of negative 4.1B yen (primarily holding company costs) reduced consolidated operating income from segment total of 7.4B yen to reported 7.0B yen.
[Profitability] ROE of 5.3% remains below the company's 2025 level and reflects subdued return on equity. Operating margin of 7.9% improved 0.3pt from 7.6% in 2025, demonstrating enhanced operational efficiency. Net profit margin of 4.8% declined from 5.3% in prior year due to special losses and higher tax burden, though remains within historical range. Gross profit margin of 30.5% remained stable, indicating consistent pricing power in core markets. [Cash Quality] Cash and deposits of 78.9B yen provide coverage of 0.22x against current liabilities of 365.8B yen. Operating cash flow of 4.3B yen represents only 0.11x of net income, signaling significant working capital absorption and weak cash conversion. Cash conversion rate (operating CF/EBITDA) of 0.04 indicates that only 4% of EBITDA converted to operating cash. [Investment Efficiency] Total asset turnover of 0.68 reflects moderate asset utilization efficiency. Return on assets of 3.3% indicates modest profitability relative to asset base. Inventory turnover period of 153 days and receivables collection period of 98 days result in a cash conversion cycle of 179 days, substantially longer than efficient peers and indicating working capital management challenges. [Financial Health] Equity ratio of 62.0% demonstrates solid financial stability with low leverage. Current ratio of 168.3% and quick ratio of 130.4% suggest adequate short-term liquidity on surface. Interest-bearing debt of 79.1B yen remains modest at 0.71x EBITDA. Debt-to-equity ratio of 0.10 reflects conservative leverage policy, though long-term borrowings increased 355.3% YoY to 56.6B yen, indicating material shift toward debt financing for growth investments.
Operating cash flow of 4.3B yen represents just 0.11x of net income of 42.7B yen, indicating substantial working capital absorption that prevented earnings from converting to cash. The primary driver was increases in inventories and receivables that consumed operating cash, resulting in exceptionally weak cash generation despite positive profitability. Investing cash flow of negative 75.7B yen was dominated by capital expenditures of 67.3B yen, representing 1.65x depreciation and amortization of 40.9B yen, reflecting aggressive investment in production capacity and infrastructure to support future growth. This investment intensity is significantly above maintenance levels and signals expansion mode. Financing cash flow of positive 65.2B yen consisted primarily of proceeds from long-term borrowings which increased 44.1B yen YoY to fund the investment program, partially offset by dividend payments. Free cash flow of negative 71.5B yen results from the combination of weak operating cash generation and substantial capital deployment. While the investment phase may yield future returns, the current period reflects significant cash consumption requiring external financing. Cash and deposits increased marginally to 78.9B yen, with the cash deficit covered through debt financing. The operating cash flow weakness driven by working capital deterioration (days sales outstanding of 98 days, inventory days of 153 days) represents a key risk factor requiring management attention to restore cash generation capability.
Ordinary income of 72.4B yen versus operating income of 70.1B yen shows non-operating net contribution of approximately 2.3B yen, primarily comprising equity method investment gains and financial income including interest and dividend income. Non-operating income represents 0.3% of revenue, indicating limited reliance on non-core sources. However, the gap between ordinary income of 72.4B yen and net income of 42.7B yen is substantial at 29.7B yen (41.0% reduction), driven by income taxes of 23.0B yen and extraordinary losses of 4.6B yen related to impairment charges. The impairment represents a non-recurring factor, though its magnitude of 6.3% of ordinary income warrants attention regarding asset quality and investment decisions. Most critically, operating cash flow of 4.3B yen falls far short of net income, with an OCF/NI ratio of 0.11, indicating poor earnings quality from a cash perspective. This divergence is explained by significant working capital increases, with inventory rising 17.9B yen YoY and accounts receivable increasing, consuming cash generated from operations. The cash conversion rate of 0.04 (operating CF to EBITDA) is exceptionally low and represents a primary earnings quality concern. While reported profits appear reasonable, the inability to convert earnings into cash suggests either aggressive revenue recognition, inventory buildup, or collection issues that diminish the quality and sustainability of reported earnings.
Full-year guidance targets Revenue of 1,177.0B yen (YoY +2.0%), Operating Income of 91.0B yen (YoY +7.4%), and Ordinary Income of 87.5B yen (YoY +6.7%). Through Q3 (9 months), progress rates stand at Revenue 74.9%, Operating Income 77.0%, and Ordinary Income 82.8% relative to full-year targets. Revenue progress of 74.9% is slightly below the standard 75.0% for Q3, suggesting modest Q4 acceleration or conservatism in the full-year target. Operating Income progress of 77.0% is above the 75.0% standard, indicating strong momentum and high likelihood of achieving or exceeding the full-year target. Ordinary Income progress of 82.8% significantly exceeds the standard, reflecting stronger-than-expected non-operating income contributions in the first nine months. The guidance assumes continued growth in the Food segment and stable Pharmaceutical performance, with margin improvement initiatives sustaining operating leverage. Given the current run rate, the company appears well-positioned to meet or exceed operating and ordinary income targets, though revenue achievement requires Q4 execution. The aggressive capital expenditure program of 67.3B yen year-to-date suggests the company is investing ahead of anticipated demand growth reflected in the +2.0% revenue forecast.
Annual dividend forecast is 52.50 yen per share for the full year, consisting of interim dividend of 26.25 yen and year-end dividend of 26.25 yen. This compares to prior year annual dividend of 50.00 yen, representing a 5.0% increase in dividend per share. Based on net income of 42.7B yen for nine months and assuming full-year net income proportional to current run rate, the implied payout ratio is approximately 72.7% using the forecast EPS of 197.80 yen and dividend of 52.50 yen, resulting in a payout ratio of 26.5%. However, this calculation requires reconciliation with full-year net income guidance. Using Q3 annualized net income would suggest a higher payout ratio in the 70-75% range, indicating strong commitment to shareholder returns. The dividend increase demonstrates management confidence despite net income decline in Q3, prioritizing stable and growing dividends as a shareholder return policy. Free cash flow of negative 71.5B yen cannot support the dividend payment, which totals approximately 14.3B yen based on 271 million shares outstanding, meaning dividends are being paid from accumulated cash or financed through borrowings. This creates sustainability concerns if free cash flow does not turn positive. No share buyback activity is disclosed in the current period. Total shareholder return is dividend-only at this stage, with the payout ratio indicating limited room for further dividend increases without cash flow improvement or net income recovery.
Working capital deterioration risk remains the most critical concern, with cash conversion cycle extended to 179 days driven by inventory days of 153 days and receivables collection of 98 days. This represents a 53-day and 27-day excess respectively versus food and beverage industry medians of 51 days and 71 days, indicating potential inventory obsolescence risk or collection difficulties that could impair asset values and further weaken cash generation. The operating cash flow to net income ratio of 0.11 quantifies this risk as severe. Capital deployment sustainability risk emerges from the combination of negative free cash flow of 71.5B yen, aggressive capital expenditure of 67.3B yen (1.65x depreciation), and dividend payments totaling approximately 14.3B yen annually. This 85.8B yen combined cash requirement exceeds operating cash generation by a wide margin, necessitating debt financing as evidenced by long-term borrowings increasing 355.3% to 56.6B yen. If investments fail to generate anticipated returns or if operating cash flow does not improve materially, the company may face constraints on sustaining both growth investments and shareholder returns simultaneously. Raw material and energy cost inflation risk impacts both Food and Pharmaceutical segments, with gross margin of 30.5% vulnerable to input cost pressures. While the company maintained gross margin stability in the current period, sustained commodity price increases or unfavorable foreign exchange movements could compress margins, particularly in the lower-margin Food segment operating at 0.8% operating margin, leaving minimal buffer for cost absorption.
[Industry Position] (Reference - Proprietary Analysis) The company operates in the food and beverage industry where FY2025 Q3 median metrics provide comparative context. Profitability metrics show ROE of 5.3% aligns closely with industry median of 5.2% (IQR: 2.3%-8.1%), indicating typical equity returns for the sector. Operating margin of 7.9% exceeds industry median of 4.9% (IQR: 3.4%-7.1%) by 3.0 percentage points, positioning the company in the upper quartile for operational efficiency. Net profit margin of 4.8% surpasses industry median of 3.4% (IQR: 2.8%-5.5%), demonstrating above-average profitability conversion. Financial health indicators reveal equity ratio of 62.0% substantially exceeds industry median of 48.0% (IQR: 44.7%-61.3%), ranking in the top quartile and indicating conservative capital structure with strong solvency. Current ratio of 1.68x falls slightly below industry median of 1.76x (IQR: 1.41x-2.38x) but remains within normal range. Efficiency metrics present mixed positioning: asset turnover of 0.68 exceeds industry median of 0.61 (IQR: 0.54-0.81), suggesting better asset utilization. However, working capital management shows challenges with inventory turnover of 153 days materially exceeding industry median of 51 days (IQR: 36-85 days) by 102 days, indicating significant inventory efficiency issues ranking in the bottom quartile. Receivables collection of 98 days also exceeds industry median of 71 days (IQR: 59-102 days), placing the company at the upper end of the range. Growth metrics show revenue growth of 0.8% lagging industry median of 3.8% (IQR: 0.6%-5.1%), positioning in the lower half of peers. The most significant deviation appears in cash conversion ratio of 0.04 versus industry median of 1.44 (IQR: 1.34-2.14), representing a critical underperformance in converting earnings to cash that ranks at the bottom of the peer group. Overall, the company demonstrates strong profitability margins and solid financial stability, but faces material challenges in working capital efficiency and cash generation relative to industry norms. (Industry: Food and Beverage, N=13 companies, Comparison: FY2025-Q3, Source: Proprietary analysis)
Operating margin leadership at 7.9% versus industry median of 4.9% demonstrates competitive advantages in cost structure and pricing power, with the company maintaining top-quartile profitability despite modest revenue growth. This margin resilience through stable gross profit margin of 30.5% and controlled SG&A spending suggests effective operational management and established market positions, particularly in the core Food segment. The aggressive capital deployment program at 1.65x depreciation signals management confidence in growth opportunities and willingness to invest through cycles. However, the stark contrast between accounting profitability and cash generation represents the defining characteristic of current performance. Operating cash flow at 0.11x net income and cash conversion ratio of 0.04 versus industry median of 1.44 reveals fundamental working capital dysfunction that prevents earnings from converting to distributable cash. Inventory days of 153 versus industry median of 51 and receivables of 98 days versus median of 71 days quantify the operational inefficiencies driving this divergence. Combined with negative free cash flow of 71.5B yen while maintaining dividends of approximately 14.3B yen and capital expenditures of 67.3B yen creates a capital allocation tension financed through 355.3% increase in long-term borrowings. The sustainability of this model depends critically on whether working capital normalizes and growth investments generate projected returns, representing the key monitoring priorities for stakeholders.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.